Features: 1. Complete supporting reagents: The self-developed supporting biochemical analyzer and biochemical reagents have better adaptability and provide more accurate test data.
2. Flexible project scheme settings: Biochemical indicators can be selected according to the actual situation. Touch-screen design simplify operation and realizes truly one-click operation, without excessive professional training.
3. Efficient project detection: The results can be obtained in 10 minutes. The process of preventing cross-contamination pollution can avoid cross-contamination between projects. The test results are accurate and reliable.
4. Excellent artificial intelligence model: WIDE & DEEP deep learning algorithm improves the recognition accuracy of the multi-factor combination model and has a high degree of coincidence.
5. Complete evaluation report output: The assignment method replaces the traditional three-segment division method to generate a complete risk assessment and diagnosis and treatment recommendation report, which is convenient for clinicians to consult.
6. Accurate test results: The reagent has a complete traceability chain, and has obtained the inter-office quality evaluation certification of the clinical inspection center of the Ministry of Health.

Based on the big data artificial intelligence technology and Deep Neural Networks (DNN), for the first time, Delta Bio applies AI artificial intelligence technology to the field of stroke prevention and screening to the intelligent stroke prevention screening system-DP-ONE. This system is an intelligent auxiliary diagnosis system that combines medical history, physical signs, biochemical indicators, and daily habits of stroke patients. It is an intelligent auxiliary diagnosis system for accurate stroke assessment and output of diagnostic reports and corresponding diagnosis and treatment recommendations. Currently V1.0 has been released and started to be applied in major hospitals or physical examination centers, which provides extremely effective help for clinicians to complete stroke risk assessment and treatment plan development for patients.